These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis. Zheng L; Zhang M; Hou J; Gong J; Nie L; Chen X; Zhou Q; Chen N Neuropathology; 2020 Dec; 40(6):599-605. PubMed ID: 32761642 [TBL] [Abstract][Full Text] [Related]
6. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Wiestler B; Capper D; Sill M; Jones DT; Hovestadt V; Sturm D; Koelsche C; Bertoni A; Schweizer L; Korshunov A; Weiß EK; Schliesser MG; Radbruch A; Herold-Mende C; Roth P; Unterberg A; Hartmann C; Pietsch T; Reifenberger G; Lichter P; Radlwimmer B; Platten M; Pfister SM; von Deimling A; Weller M; Wick W Acta Neuropathol; 2014 Oct; 128(4):561-71. PubMed ID: 25008768 [TBL] [Abstract][Full Text] [Related]
7. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide. Speirs CK; Simpson JR; Robinson CG; DeWees TA; Tran DD; Linette G; Chicoine MR; Dacey RG; Rich KM; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):268-76. PubMed ID: 25636755 [TBL] [Abstract][Full Text] [Related]
8. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion. Chen SC; Lo CM; Wang SH; Su EC BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275 [TBL] [Abstract][Full Text] [Related]
9. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179 [TBL] [Abstract][Full Text] [Related]
11. Anaplastic glioma: current treatment and management. Le Rhun E; Taillibert S; Chamberlain MC Expert Rev Neurother; 2015 Jun; 15(6):601-20. PubMed ID: 25936680 [TBL] [Abstract][Full Text] [Related]
12. Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas. Rajmohan KS; Sugur HS; Shwetha SD; Pandey P; Arivazhagan A; Santosh V Neurol India; 2020; 68(4):832-837. PubMed ID: 32859823 [TBL] [Abstract][Full Text] [Related]
13. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154 [TBL] [Abstract][Full Text] [Related]
14. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas. Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432 [TBL] [Abstract][Full Text] [Related]
15. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927 [TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D; Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687 [TBL] [Abstract][Full Text] [Related]
17. Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas. Alentorn A; van Thuijl HF; Marie Y; Alshehhi H; Carpentier C; Boisselier B; Laigle-Donadey F; Mokhtari K; Scheinin I; Wesseling P; Ylstra B; Capelle L; Hoang-Xuan K; Sanson M; Delattre JY; Reijneveld JC; Idbaih A Neuro Oncol; 2014 Mar; 16(3):400-8. PubMed ID: 24335697 [TBL] [Abstract][Full Text] [Related]
18. Static and dynamic Verger A; Stoffels G; Bauer EK; Lohmann P; Blau T; Fink GR; Neumaier B; Shah NJ; Langen KJ; Galldiks N Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):443-451. PubMed ID: 29043400 [TBL] [Abstract][Full Text] [Related]
19. Reduced H3K27me3 levels in diffuse gliomas: association with 1p/19q codeletion and difference from H3K27me3 loss in malignant peripheral nerve sheath tumors. Kitahama K; Iijima S; Sumiishi A; Hayashi A; Nagahama K; Saito K; Sasaki N; Kobayashi K; Shimizu S; Nagane M; Shibahara J Brain Tumor Pathol; 2021 Jan; 38(1):23-29. PubMed ID: 32989606 [TBL] [Abstract][Full Text] [Related]
20. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]